AEAllison Ross Eckard

Allison Ross Eckard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Allison Ross Eckard has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Grace A. McComsey

    Department of Pediatrics, University Hospitals Cleveland Medical Center, Cleveland, OH; and

    12 shared publications
  • Danielle Labbato

    Department of Medicine, Division of Infectious Diseases, University Hospitals Cleveland Medical Center, Cleveland, OH, USA

    8 shared publications
  • Mary Ann O'RIordan

    Department of Pediatrics, University Hospitals Cleveland Medical Center, Cleveland, OH; and

    7 shared publications
  • Ann Chahroudi

    Emory University School of Medicine Atlanta, Georgia, USA

    5 shared publications
  • Monika Uribe-Leitz

    Emory University School of Medicine Atlanta, Georgia, USA

    5 shared publications
  • Joshua H. Ruff

    B Emory University School of Medicine , Atlanta , GA , USA

    4 shared publications

Latest Publications

  • Open Access

    Effects of semaglutide on subclinical cardiovascular health in people with HIV

    by Joviane Daher, Ziad Koberssy, Nicolas Moussallem, Qian Wu, Abdus Sattar, Aaron A. Fletcher, Christian M. McComsey, Nicholas T. Funderburg, Kate Ailstock, Alisson Ross Eckard

    Design and objective: Lipohypertrophy, characterized by central adipose tissue accumulation, is common in people with HIV (PWH) and contributes to cardiometabolic risk. In a recent randomized, double-blind, placebo-controlled phase 2b trial, semaglutide significantly improved weight, total fat, visceral adiposity, blood pressure, glucose metabolism, and lipids over 32 weeks in PWH with lipohypertrophy. This prespecified secondary analysis evaluated semaglutide's effects on subclinical cardiovascular health. Methods: Virologically suppressed adults with HIV without known diabetes, receiving stable antiretroviral therapy, with body mass index >25 kg/m 2 and increased waist circumference/waist-to-hip ratio were enrolled. Participants were randomized 1 : 1 to semaglutide or placebo for 32 weeks. Pulse wave velocity (PWV) and endothelial peripheral arterial tonometry (endoPAT) assessed arterial stiffness and endothelial function, and coronary artery calcium (CAC) score assessed calcified coronary atherosclerosis. Indirect calorimetry measured resting energy expenditure (REE) and oxygen consumption (VO 2 ). 10-year atherosclerotic cardiovascular disease (ASCVD) risk scores were calculated. Analyses followed intention-to-treat principles using sex-adjusted multiplicative regression. Results: One hundred eight participants ( n = 54 semaglutide) were enrolled (median age 53 years; 60% male; 65% non-White; 35% smokers). Semaglutide had no significant effect on PWV, CAC score, reactive hyperemia index, augmentation index, or REE. VO 2 showed a downward trend ( β −43 ml/min; P = 0.087). At week 32, significant reductions were observed in 10-year ASCVD risk (−32.6%; P = 0.026) and hsCRP (−23.4%; P = 0.02) in the semaglutide group relative to placebo. Conclusion: Semaglutide did not improve subclinical vascular markers over 32 weeks but significantly improved overall cardiometabolic health and cardiovascular disease risk. Longer and larger studies of GLP-1 RAs are indicated in HIV to further assess their effects on long-term cardiovascular disease outcomes. Trial registration: NCT04019197.

  • Top Cited Papers

    Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial

    by Allison Ross Eckard, Qian Wu, Abdus Sattar, Kianoush Ansari-Gilani, Danielle Labbato, Theresa Foster, Aaron A Fletcher, Ruth O Adekunle, Grace A McComsey


  • Open Access

    Optimizing the Implementation of Tobacco Treatment for People with HIV: A Pilot Study

    by Madeline G. Foster, Benjamin A. Toll, Emily Ware, Allison Ross Eckard, Katherine R. Sterba, Alana M. Rojewski

    People with HIV (PWH) have higher rates of tobacco use compared to their societal counterparts and are disproportionately affected by tobacco-related morbidity and mortality. A needs assessment was conducted to assess provider beliefs and opinions on tobacco treatment barriers and treatment approaches. The results highlighted a disconnect between the known importance of quitting smoking and barriers in linking patients to treatment, such as lack of patient interest and other patient issues being a higher priority. Using this assessment data, a treatment delivery approach, Proactive Outreach with Medication Opt-out for Tobacco Treatment Engagement (PrOMOTE), was devised and piloted. PrOMOTE consisted of an outpatient clinical pharmacist trained in tobacco treatment proactively contacting patients for counseling and to prescribe smoking cessation pharmacotherapy (varenicline or dual nicotine replacement therapy (NRT)) using an opt-out approach. The pilot was conducted with 10 PWH and patient reach and opt-out rates were evaluated. Of the 10 patients contacted, 7 were reached and none opted out of the pharmacotherapy prescription (varenicline = 6; NRT = 1). Providers know the importance of smoking cessation for PWH but encounter several barriers to implementing treatment. Using PrOMOTE methods to deliver tobacco treatment increased the reach and pharmacotherapy acceptance rate of PWH who smoke.


  • Remestemcel-L Therapy for COVID-19–Associated Multisystem Inflammatory Syndrome in Children

    by Allison Ross Eckard, Kenneth M. Borow, Elizabeth H. Mack, Elizabeth Burke, Andrew M. Atz

    Multisystem inflammatory syndrome in children (MIS-C) is a serious postinfectious immune dysregulation associated with coronavirus disease 2019 that may present with severe and life-threatening cardiovascular dysfunction, hemodynamic instability, shock, and multisystem organ failure. Optimal treatment is unknown. Current standard of care consists of nonspecific anti-inflammatory and antithrombotic therapies. Interventions that target MIS-C’s distinctive clinical features and immunophenotype are indicated. Remestemcel-L, an investigational mesenchymal stromal cell therapy, is a promising candidate for treatment of MIS-C because of its beneficial anti-inflammatory, immunomodulatory, endothelial function and vascular stabilizing effects, which align well with the pathophysiology of MIS-C. Here, we present the first two patients with life-threatening MIS-C ever treated with remestemcel-L under an expanded access program. Both were previously healthy children without any indication of previous coronavirus disease 2019 infection or exposure. They presented with severe clinical illness including myocardial dysfunction, hemodynamic instability, hypotension, acute kidney injury, and shock. At the time of hospital admission, both had negative polymerase chain reaction (PCR) test results and positive serology results for severe acute respiratory syndrome coronavirus 2. Both children received standard of care MIS-C treatment. Although the patients showed some clinical improvement, left ventricular ejection fraction remained reduced and inflammatory biomarkers remained significantly elevated. When treated with two intravenous doses of remestemcel-L separated by 48 hours, rapid normalization of left ventricular ejection fraction, notable reductions in biomarkers of systemic and cardiac inflammation, and improved clinical status occurred. Neither child experienced adverse effects associated with remestemcel-L administration. This treatment appears promising as a novel immunomodulatory cellular therapy for children with clinically significant cardiovascular manifestations of MIS-C.


  • Fecal Calprotectin Is Elevated in HIV and Related to Systemic Inflammation

    by Allison Ross Eckard, Heather Y. Hughes, Nancy L. Bs Hagood, Mary Ann O'RIordan, Danielle Labbato, Julia C. Kosco, Sarah E. Scott, Grace A. McComsey

    Background: Fecal calprotectin (FC), a biomarker of gastrointestinal (GI) inflammation, is used in the diagnosis and management of inflammatory bowel disease. HIV infection severely damages gut-associated lymphoid and epithelial tissues leading to GI inflammation that drives systemic inflammation and increases subsequent risk of comorbidities. For the first time, we compared FC concentrations by HIV and antiretroviral therapy (ART) status and determined the relationship to systemic inflammation. Methods: People with and without HIV were enrolled and underwent a comprehensive clinical and laboratory assessment. Stool samples were collected, and FC was measured by enzyme-linked immunosorbent assay ELISA. Plasma biomarkers of inflammation were also measured. Results: One hundred one participants with HIV (83 ART-treated and 18 ART-naive) and 89 uninfected controls were enrolled. There were no significant differences between ART-naive and ART-treated participants, but both HIV groups had significantly higher FC concentrations than controls when FC was considered as a continuous variable or by cut-offs used in inflammatory bowel disease. The highest median and largest proportion of participants with FC >100 µg/g were seen in ART-naive, followed by ART-treated and then controls. Among HIV participants, FC concentrations were positively associated with high-sensitivity C-reactive protein, soluble tumor necrosis factor receptor II, and soluble vascular cellular adhesion molecule and inversely associated with CD4 counts. Conclusions: FC concentrations are elevated in HIV regardless of ART status. ART and immune reconstitution seem to reduce FC but not to concentrations seen in uninfected controls. Our results suggest a role for FC as a noninvasive surrogate measurement of GI inflammation and associated systemic inflammation in HIV.


  • Fibroblast Growth Factor 21 Is Elevated in HIV and Associated With Interleukin-6

    by Allison Ross Eckard, Heather Y. Hughes, Nancy L. Bs Hagood, Mary A. O'RIordan, Danielle Labbato, Julia C. Kosco, Sarah E. Scott, Grace A. McComsey


  • Weight gain and integrase inhibitors

    by Allison Ross Eckard, Grace A. McComsey

    Purpose of review: Weight gain and obesity among people living with HIV (PLWH) is a serious problem that occurs often after initiation of antiretroviral therapy but may be worse with integrase strand transfer inhibitors (INSTIs). This article comprehensively reviews available data and summarizes our current understanding of the topic. Recent findings: Recent studies support the concept that weight gain and treatment emergent obesity are worse with INSTI-based regimens, particularly dolutegravir. Women and nonwhites appear to be the most at risk, and the accompanying nucleoside reverse transcriptase inhibitor may play a role. Lipohypertrophy, an abnormal accumulation of visceral fat and/or ectopic fat depots, continues to be a problem among PLWH, but the role of INSTIs is inconsistent. The pathogenesis of weight gain and changes in body composition in HIV, especially with INSTIs, is poorly understood but may lead to serious comorbidities, such as cardiovascular disease and diabetes. Summary: Although INSTI-based regimens are highly efficacious for viral suppression, they appear to cause more weight gain and treatment emergent obesity than non-INSTI-based regimens and may increase the risk of weight-related comorbidities. More studies are needed to understand the pathogenesis of weight gain with INSTIs in PLWH, in order to prevent this serious complication.


  • Contemporary Issues in Pregnancy (and Offspring) in the Current HIV Era

    by Allison Ross Eckard, Stephanie E. Kirk, Nancy L. Hagood

    Purpose of Review Although antiretroviral therapy (ART) has dramatically reduced mother to child transmission of HIV, data continue to mount that infants exposed to HIV in utero but are not infected (HEU) have serious negative health consequences compared to unexposed infants. This review evaluates recent literature on contemporary issues related to complications seen in pregnant women with HIV and their offspring. Recent Findings Current studies show that HEU infants are at a high risk of adverse outcomes, including premature birth, poor growth, neurodevelopmental impairment, immune dysfunction, infectious morbidity, and death. Etiologies for the observed clinical events and subclinical alterations are complex and multifactorial, and the long-term consequences of many findings are yet unknown. Summary HEU infants have an unacceptable rate of morbidity and mortality from perinatal HIV and ART exposure, even in the modern ART era. Continual monitoring and reporting is imperative to protect this vulnerable population in our everchanging landscape of HIV treatment and prevention.


  • Effects of Vitamin D Supplementation on Bone Mineral Density and Bone Markers in HIV-Infected Youth

    by Allison Ross Eckard, Mary Ann O'RIordan, Julia C. Do Rosebush, Joshua H. Bs Ruff, Ann Chahroudi, Danielle Bn Labbato, Julie E. Bn Daniels, Monika Uribe-Leitz, Vin Tangpricha, Grace A. McComsey

    Background: Low bone mineral density (BMD) is a significant comorbidity in HIV. However, studies evaluating vitamin D supplementation on bone health in this population are limited. This study investigates changes in bone health parameters after 12 months of supplementation in HIV-infected youth with vitamin D insufficiency. Methods: This is a randomized, active-control, double-blind trial investigating changes in bone parameters with 3 different vitamin D3 doses [18,000 (standard/control dose), 60,000 (moderate dose), and 120,000 IU/monthly (high dose)] in HIV-infected youth 8–25 years old with baseline serum 25-hydroxyvitamin D (25(OH)D) concentrations P = 0.001) and Β-CrossLaps (−0.13 ng/mL; P = 0.0005). Conclusions: High-dose vitamin D supplementation (120,000 IU/mo) given over 12 months decreases bone turnover markers in HIV-infected youth with vitamin D insufficiency, which may represent an early, beneficial effect on bone health. High vitamin D doses are needed to maintain optimal serum 25(OH)D concentrations.


  • Open Access

    Effects of vitamin D supplementation on carotid intima-media thickness in HIV-infected youth

    by Allison Ross Eckard, Paolo Raggi, Mary Ann O'RIordan, Julia C. Rosebush, Danielle Labbato, Ann Chahroudi, Joshua H. Ruff, Christopher T. Longenecker, Vin Tangpricha, Grace A. McComsey

    (2018). Effects of vitamin D supplementation on carotid intima-media thickness in HIV-infected youth. Virulence: Vol. 9, No. 1, pp. 294-305.